Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study

Authors

Institutions

Publication Details

Journal
The Lancet Microbe
Published
2026-02-17
DOI
https://doi.org/10.1016/j.lanmic.2025.101283
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study

Javier O Morales-Ramirez, Linda Gorgos, Kwad Mponponsuo, Joseph Eron et al.
The Lancet Microbe
HIV/AIDS drug development and treatment
article

Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study

Javier O Morales-Ramirez, Linda Gorgos, Kwad Mponponsuo, Joseph Eron, Hailin Huang, Nan Zhang, Onyema Ogbuagu, James H McMahon, Aditya Gaur, Laurie A VanderVeen, Kimberly Workowski, Jason Brunetta, Sean E Collins
article en

Abstract

No abstract available for this paper.
The Lancet MicrobeVol. 7(3)
University of North Carolina at Chapel Hill (US), St. Jude Children's Research Hospital (US), Emory University (US), The Alfred Hospital (AU), Yale University (US), Monash Alfred Psychiatry Research centre (AU), Clinical Research Puerto Rico (PR), Maple Leaf Medical Clinic (CA), Gilead Sciences (United States) (US), Monash University (AU)
Zero hunger
Openalex Percentile: Top 52%
HIV/AIDS drug development and treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study — Javier O Morales-Ramirez, Linda Gorgos, et al. · The Lancet Microbe (2026) | TGRS Research Map | TGRS